Advertisement

Table of contents

  1. Front Matter
    Pages I-XIX
  2. Mechanisms of Action

    1. Front Matter
      Pages 1-1
    2. J. Sandow, H. M. Fraser, K. Engelbart, H. Seidel, H. Donaubauer, W. von Rechenberg
      Pages 10-21
    3. J. A. Foekens, J. G. M. Klijn
      Pages 22-29
  3. Prostatic Cancer

    1. Front Matter
      Pages 31-31
    2. A. Dupont, F. Labrie, M. Giguère, J. P. Borsanyi, Y. Lacourciere, A. Bélanger et al.
      Pages 60-71
    3. G. H. Jacobi, U. K. Wenderoth, H. v. Wallenberg, M. Gatto, R. Hohenfellner
      Pages 72-88
  4. Protection of Spermatogenesis

  5. Breast Cancer

    1. Front Matter
      Pages 129-129
    2. H. A. Harvey, A. Lipton, D. T. Max
      Pages 131-138
    3. K. Höffken, R. Becher, E. Kurschel, C. Doberauer, C. U. Anders, R. Callies et al.
      Pages 149-163
    4. N. Niederle
      Pages 183-183
  6. Back Matter
    Pages 185-188

About these proceedings

Introduction

Hormonal treatment of malignant diseases came of age quite some years ago. Nevertheless, developments in this field are still progressing at a steady pace. During recent years, the detection of new endocrine feedback loops and the availability of new classes of hormonal agents made it possible to predictively interfere with hor­ mone actions. Besides the intellectual challenge of modulating the hormone system, there is an important new aspect associated with recent research on hormones and cancer: new developments have generally led to a reduction in treatment-induced morbidity. As aromataseinhibitors are substituted for adrenalectomy, controlled interference with the hypothalamic-gonadotrophic axis is likely to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. With the detection of the luteinizing hormone releasing hormone (LH-RH), its structural analysis, and the synthesis of analogs of this decapeptide hormone, a tool became available not only for treatment of sterility or endometriosis but also for switching off gonadal activity in a reversible manner. Evidence has accumulated over the past few years that LH-RH agonists can serve as "medical orchiectomy" in prostate cancer. As a logical consequence, hypogonadotropic gonadal insufficiency induced by LH-RH agonists was investigated in patients with breast cancer. Of equal importance were the attempts to prevent infertility from cytostatic drugs by temporar­ ily suspending gonadal function.

Keywords

Gonadotropin cancer carcinoma chemotherapy clinical trial fertility hormone hormones infertility oncology prevention prostate cancer spermatogenesis

Editors and affiliations

  • Klaus Höffken
    • 1
  1. 1.Innere Klinik und Poliklinik Westdeutsches TumorzentrumUniversitätsklinikum EssenEssen 1Federal Republic of Germany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-73530-1
  • Copyright Information Springer-Verlag Berlin Heidelberg 1988
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-73532-5
  • Online ISBN 978-3-642-73530-1
  • Buy this book on publisher's site